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Tumor exosome-based nanoparticles are efﬁcient
drug carriers for chemotherapy
Tuying Yong 1,2,6, Xiaoqiong Zhang1,6, Nana Bie1,6, Hongbo Zhang3,6, Xuting Zhang 1, Fuying Li1,
Abdul Hakeem1, Jun Hu1, Lu Gan 1,2, Hélder A. Santos 4,5 & Xiangliang Yang1,2
Developing biomimetic nanoparticles without loss of the integrity of proteins remains a major
challenge in cancer chemotherapy. Here, we develop a biocompatible tumor-cell-exocytosed
exosome-biomimetic porous silicon nanoparticles (PSiNPs) as drug carrier for targeted
cancer chemotherapy. Exosome-sheathed doxorubicin-loaded PSiNPs (DOX@E-PSiNPs),
generated by exocytosis of the endocytosed DOX-loaded PSiNPs from tumor cells, exhibit
enhanced tumor accumulation, extravasation from blood vessels and penetration into
deep tumor parenchyma following intravenous administration. In addition, DOX@E-PSiNPs,
regardless of their origin, possess signiﬁcant cellular uptake and cytotoxicity in both bulk
cancer cells and cancer stem cells (CSCs). These properties endow DOX@E-PSiNPs with
great in vivo enrichment in total tumor cells and side population cells with features of CSCs,
resulting in anticancer activity and CSCs reduction in subcutaneous, orthotopic and
metastatic tumor models. These results provide a proof-of-concept for the use of exosome-
biomimetic nanoparticles exocytosed from tumor cells as a promising drug carrier for
efﬁcient cancer chemotherapy.
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Nanoparticles-based drug delivery systems (NDDSs) haveshown promising therapeutic efﬁcacy in cancer due to theenhanced permeability and retention (EPR) effect1,2. To
increase the capacity of targeting delivery of anticancer drugs to
tumors, nanoparticles are usually functionalized with targeted
antibodies, peptides or other biomolecules3,4. However, the pre-
sence of targeting ligands may sometimes have a negative inﬂu-
ence on nanoparticle delivery owing to the enhanced immune-
elimination5. Moreover, the targeting of these functionalized
nanoparticles using targeting ligands is not possible and not
precise for a wide range of cancers, because the receptors differ
from versatile genetic or phenotypic heterogeneity of tumors6,7.
Biomimetic nanoparticles that combine the unique function-
alities of natural biomaterials, such as cells or cell membranes,
and engineering versatility of synthetic nanoparticles have
recently increased considerable attention as effective drug delivery
platforms8,9. Nanoparticles can be coated by various cell
membranes from red blood cells (RBCs)10,11, cancer cells12,13,
platelets14, or white blood cells (WBCs)15, and have displayed
good biocompatibility, prolonged circulation, as well as tumor-
targeting capacity. Exosomes are small extracellular vesicles
secreted by mammalian cells16, and have lately been used as
attractive nanocarriers owing to their stability in circulation,
biocompatibility, low immunogenicity and low toxicity17–19.
Furthermore, the exosomes display efﬁcient cellular uptake and
target-homing capabilities dependent on the proteins of their
membrane17–19. Given that the surface protein composition of
exosomes may be crucial to their function, preservation of exo-
some membrane integrity and stability is very important for their
application in drug delivery20. Generally, exosomes-biomimetic
nanoparticles are constructed by iterative physical extrusion or
freeze/thaw cycles to fuse exosomes and nanoparticles21,22, which
might affect the protein integrity on exosome membranes,
thereby compromising the biofunctions of these biomimetic
nanoparticles23,24. Therefore, it is highly desired to develop an
efﬁcient approach to construct exosome-biomimetic nano-
particles without interfering with the membrane integrity for
cancer therapy.
Luminescent porous silicon nanoparticles (PSiNPs) have been
widely used as drug carriers owing to their excellent drug loading
capacity, high biocompatibility and biodegradability15,25–30.
Here, we develop a biocompatible tumor cell-exocytosed exo-
some-sheathed PSiNPs (E-PSiNPs) as a drug carrier for targeted
cancer chemotherapy. When tumor cells are incubated with
doxorubicin-loaded PSiNPs (DOX@PSiNPs), they exocytose
exosome-sheathed DOX-loaded PSiNPs (DOX@E-PSiNPs)
(Fig. 1a). DOX@E-PSiNPs, regardless of the exosome origin,
possess strong cross-reactivity of cellular uptake and cytotoxicity
against bulk cancer cells and cancer stem cells (CSCs), which are
responsible for tumorgenesis, tumor progression, recurrence,
metastasis and drug resistance31,32. Moreover, DOX@E-PSiNPs
exhibit enhanced tumor accumulation, extravasation from blood
vessels and deep penetration into tumor parenchyma. These
features of DOX@E-PSiNPs result in their greater in vivo
enrichment in total tumor cells and side population cells with
characteristics of CSCs33,34, thus generating remarkable antic-
ancer and CSCs killing activity in subcutaneous, orthotopic and
metastatic tumors (Fig. 1b). Our study provides a approach for
cancer therapy by using exosome-biomimetic nanoparticles exo-
cytosed from tumor cells as drug carriers to efﬁciently deliver
anticancer drug.
Results
Autophagy-involved in the exocytosis of PSiNPs. Luminescent
PSiNPs were prepared by electrochemical etching of silicon
wafers, lift-off of PSi ﬁlm, ultrasonication, centrifugation and
ﬁnally activation of luminescence by heating in an aqueous
solution. The hydrodynamic diameter of PSiNPs was ca. 150 nm
measured by dynamic light scattering (DLS, Supplementary
Fig. 1a). Scanning electron microscope (SEM) image showed a
meso-porous nanostructure of the PSi ﬁlm with the pore diameter
of ca. 11 nm (Supplementary Fig. 1b). The BET surface area, pore
volume and average pore diameter of PSiNPs were 211.8 m2 g−1,
0.2 cm2 g−1, and 13.5 nm as measured by nitrogen adsorption
analysis (Supplementary Fig. 1c), respectively. The intrinsic
photoluminescence of PSiNPs under 488 nm excitation appeared
at wavelengths between 600 and 800 nm (Supplementary Fig. 1d).
Human hepatocarcinoma Bel7402 cells were treated with
PSiNPs for 6 h, followed by washing thoroughly with PBS and
then incubating in fresh nanoparticle-free medium for different
time intervals. Inductively coupled plasma-optical emission
spectroscopy (ICP-OES) analysis showed that PSiNPs were
exocytosed from Bel7402 cells in a time-dependent manner,
and ca. 96% of PSiNPs were expelled out after culture in fresh
medium for 18 h (Supplementary Fig. 2). Autophagy is a highly
regulated process for intracellular homeostasis through clearance,
degradation, or exocytosis of damaged cell components or foreign
risks35. Thus, the exocytosis of PSiNPs may have high relevance
to autophagy. To elucidate the role of autophagy in the exocytosis
of PSiNPs, we ﬁrst sought to determine whether PSiNPS-induced
autophagy. Bel7402 cells were treated with PSiNPs for different
time intervals and then the ratio of endogenous microtubule-
associated protein 1 light chain 3 (LC3)-II to LC3-I was assessed,
since cytosolic LC3-I is conjugated to phosphatidylethanolamine
to form membrane-associated LC3-II, which is recruited to
autophagosomal membranes during autophagy, and therefore the
conversion of LC3-I to LC3-II is considered to be an accurate
indicator of autophagic activity36. PSiNPs treatment resulted in
an increase of the ratio of LC3-II to LC3-I in a time-dependent
manner (Fig. 2a), suggesting that PSiNPs treatment induces a
cumulative increase in the formation of autophagosomes. Similar
result was observed in murine hepatocarcinoma H22 cells
(Supplementary Fig. 3), revealing that this phenomenal was not
cell dependent. Bel7402 cells were also transfected with EGFP-
LC3 plasmid and then treated with PSiNPs for different time
intervals. Consistently, treatment with PSiNPs led to signiﬁcantly
enhanced puncta formation of LC3-labeled vacuoles (Fig. 2b),
conﬁrming that PSiNPs-induced autophagosome formation.
Moreover, we observed intracellular PSiNPs captured in the
LC3+ autophagosomes (Fig. 2b). To determine whether autop-
hagy was involved in the exocytosis of PSiNPs, we exposed
Bel7402 cells with PSiNPs in the presence or absence of
autophagy inhibitor 3-methyladenine (3-MA), or autophagy
inducers rapamycin and carbamazepine (CBZ). 3-MA signiﬁ-
cantly inhibited the exocytosis of PSiNPs, while both rapamycin
and CBZ signiﬁcantly enhanced the exocytosis of PSiNPs (Fig. 2c),
indicating that autophagy mediates the exocytosis of PSiNPs.
Furthermore, the exocytosis of PSiNPs from Atg7 (a crucial
autophagy gene)-deﬁcient (Atg7−/−) mouse embryonic ﬁbro-
blasts (MEFs) was signiﬁcantly lower than that from wild type
MEFs (Fig. 2d), conﬁrming that PSiNPs-induced autophagy
regulates their exocytosis after internalization.
Exosomes sheathed with PSiNPs (E-PSiNPs). After Bel7402 cells
were incubated with PSiNPs, we collected the exocytosed PSiNPS
(E-PSiNPs) by centrifugation. Field transmission electron
microscope (FTEM) energy spectrum analysis showed that silicon
was detected in E-PSiNPs (Supplementary Fig. 4), endorsing that
E-PSiNPs were actually the exocytosed PSiNPs. DLS analysis
showed that the size of E-PSiNPs and PSiNPs was 260 ± 15 nm
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and 150 ± 11 nm, and the corresponding PDI was 0.145 ± 0.032
and 0.208 ± 0.028, respectively (Fig. 3a). The zeta-potential of
E-PSiNPs and PSiNPs was −11.0 ± 0.4 mV and −10.8 ± 0.2 mV.
TEM images revealed that PSiNPs and E-PSiNPs displayed irre-
gular morphology, and ca. 20 nm thick membrane appeared on
the surface of E-PSiNPs compared with PSiNPs (Fig. 3b). To
further prove that PSiNPs were sheathed with membrane struc-
ture in E-PSiNPs, 3,3′-dioctadecyloxacarbocyanine perchlorate
(DiO), a commonly used cell membrane ﬂuorescent probe, was
used to stain E-PSiNPs. Colocalization of green DiO ﬂuorescence
with intrinsic red PSiNPs ﬂuorescence was observed in E-PSiNPs,
but not in PSiNPs by confocal microscopy (Fig. 3c), conﬁrming
the presence of the membrane sheathed on PSiNPs in E-PSiNPs.
Exosomes, derived from fusion of intraluminal vesicles in
MVBs with plasma membrane, serve as highly efﬁcient export
vehicles17–19. When internalized into Bel7402 cells, PSiNPs were
found to be colocalized with FITC-CD63-labeled MVBs (Supple-
mentary Fig. 5), suggesting that PSiNPs are associated with MVBs
before exocytosis. To explore whether E-PSiNPs were sheathed
with exosomes, FITC-conjugated CD63 (a common biomarker
for exosomes) antibody was used to label E-PSiNPs exocytosed
from Bel7402 cells. As shown by immunoﬂuorescent staining,
CD63 was detected in E-PSiNPs, but not in PSiNPs (Fig. 3d).
Western blot experiments further showed that similar to
the whole cell lysates and the puriﬁed exosomes obtained by
differential ultracentrifugation37,38, exosome biomarkers TSG101
and CD63 were also detected in E-PSiNPs (Fig. 3e), conﬁrming
the presence of exosomes in E-PSiNPs. In contrast to exosome
biomarkers, calnexin, a protein located in endoplasmic reticulum
(ER)39, was only detected in whole cell lysates, but not in both
E-PSiNPs and the puriﬁed exosomes (Fig. 3e), revealing the high
purity of the exosomes sheathed on PSiNPs in E-PSiNPs. Similar
results were also observed in E-PSiNPs exocytosed from H22
cells (Supplementary Fig. 6), suggesting that E-PSiNPs can be
generated from different cell lines. Moreover, dimethyl amiloride
(DMA), an inhibitor of exosome release by disrupting calcium
signaling40, was found to signiﬁcantly inhibit the yield of
E-PSiNPs, while ionomycin, a promoter of exosome release by
increasing intracellular calcium concentration41, signiﬁcantly
augmented the yield of E-PSiNPs (Fig. 3f).
Overall, these results strongly conﬁrm that the membrane that
sheathed PSiNPs in E-PSiNPs is exosomes. The total protein
amount of E-PSiNPs exocytosed from 107 cancer cells was 60 μg,
but only 1.8 μg proteins were detected in the naturally secreted
exosomes from equal numbers of cancer cells by differential
ultracentrifugation, which was consistent with the other group’s
report21. The fact that PSiNPs stimulated the production of
exosomes by nearly 34 times shows that E-PSiNPs can be
prepared with relatively high yield.
E-PSiNPs as a drug carrier. E-PSiNPs as a drug carrier were
investigated using DOX as a model drug. DOX was loaded into
PSiNPs and then incubated with Bel7402 cells. Exosome-sheathed
DOX-loaded PSiNPs (DOX@E-PSiNPs) were also obtained by
centrifugation in a similar fashion to E-PSiNPs. The colocaliza-
tion of DOX, DiO-labeled membrane and PSiNPs by immuno-
ﬂuorescent staining showed the successful encapsulation of DOX
into E-PSiNPs exocytosed from Bel7402 cells (Fig. 4a). DOX can
also be encapsulated into E-PSiNPs exocytosed from H22 cells
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Fig. 1 Schematic illustration of E-PSiNPs as drug carriers for targeted cancer chemotherapy. a Schematic illustration of the preparation of DOX@E-PSiNPs.
DOX@PSiNPs are endocytosed into cancer cells after incubation, then localized in multivesicular bodies (MVBs) and autophagosomes. After MVBs or
amphisomes fuse with cell membrane, DOX@E-PSiNPs are exocytosed into extracellular space. b Schematics showing how DOX@E-PSiNPs effeciently target
tumor cells after intravenous injection into tumor-bearing mice. (I) DOX@E-PSiNPs effeciently accumulate in tumor tissues; (II) DOX@E-PSiNPs penetrate
deeply into tumor parenchyma; and (III) DOX@E-PSiNPs are efﬁcently internalized into bulk cancer cells and CSCs to produce strong anticancer efﬁcacy
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using the same processing method (Supplementary Fig. 7). The
drug loading degree of DOX@E-PSiNPs was 300 ng DOX μg−1
protein (exosomes were quantiﬁed according to the protein
content) and the drug loading efﬁciency was 0.8% determined by
high performance liquid chromatography (HPLC). DOX loading
did not signiﬁcantly change the size of E-PSiNPs (Fig. 4b).
Moreover, the size of DOX@E-PSiNPs remained almost constant
even after incubating in PBS with or without 10% fetal bovine
serum (FBS) for 6 days (Fig. 4c). Furthermore, storage at −80 °C
for 1 month or lyophilization followed by resuspension in PBS
1 week later did not affect the size (Supplementary Fig. 8a, d) and
zeta-potential (Supplementary Fig. 8b, e) of DOX@E-PSiNPs.
Furthermore, relatively little degradation (Fig. 4d) and no sig-
niﬁcant morphology change (Supplementary Fig. 9) of DOX@E-
PSiNPs were detected after 72 h incubation in PBS. These results
demonstrate that DOX@E-PSiNPs are relatively stable. DOX@E-
PSiNPs showed a sustained drug release proﬁle as compared to
DOX@PSiNPs (Fig. 4e), which can avoid the side effects caused
by DOX burst release during blood circulation.
Efﬁcient cellular uptake and cytotoxicity. To explore the bio-
logical function of DOX@E-PSiNPs, the interaction of DOX@E-
PSiNPs with CSCs with high drug resistance was ﬁrst investi-
gated. The H22 CSCs tumor spheroids were selected by the
previously reported soft three-dimensional (3D) ﬁbrin gel
method42,43. Intracellular DOX ﬂuorescence increased in a dose-
dependent manner in H22 CSCs treated with free DOX,
DOX@PSiNPs or DOX@E-PSiNPs exocytosed from H22 cells
(Fig. 5a). However, DOX@E-PSiNPs displayed the highest
intracellular accumulation, which was ca. 2.1 and 1.7 times more
than free DOX and DOX@PSiNPs, respectively (Fig. 5a).
DOX@E-PSiNPs after storage at −80 °C for 1 month or lyophi-
lization followed by resuspension in PBS 1 week later still
exhibited similarly strong cellular uptake by H22 CSCs (Supple-
mentary Fig. 8c, f). Furthermore, the intracellular DOX retention
in H22 CSCs was determined after treatment with free DOX,
DOX@PSiNPs or DOX@E-PSiNPs exocytosed from H22 cells for
2 h, followed by washing with PBS and then incubating in fresh
medium for different time intervals. Treatment with DOX@E-
PSiNPs resulted in the enhanced DOX retention in H22 CSCs
compared with free DOX or DOX@PSiNPs (Supplementary
Fig. 10a). The enhanced DOX retention in DOX@E-PSiNPs-
treated H22 CSCs might be due to the decreased expression of
multidrug-resistant protein P-glycoprotein (P-gp) (Supplemen-
tary Fig. 10b), a plasma membrane transporter whose expression
was associated with cell membrane microenvironment44.
DOX@E-PSiNPs-induced decrease in P-gp expression might be
due to the strong interaction with cell membrane (Supplementary
Fig. 11a, b), reducing the cell membrane ﬂuidity (Supplementary
Fig. 11c). Correspondingly, fewer H22 tumor spheroids were
formed when H22 cells were pretreated with DOX@E-PSiNPs
exocytosed from H22 cells for 4 h and then seeded in soft 3D
ﬁbrin gels (90 Pa, 400 cells per well) for 5 days as compared to
those pretreated with free DOX or DOX@PSiNPs (Fig. 5b).
Moreover, colony sizes were reduced signiﬁcantly in DOX@E-
PSiNPs-pretreated group (Fig. 5c). On the other hand, when H22
CSCs selected by soft 3D ﬁbrin gels were treated with free DOX,
DOX@PSiNPs or DOX@E-PSiNPs exocytosed from H22 cells for
24 h, DOX@E-PSiNPs also exhibited the strongest inhibition in
colony number and size of tumor spheroids (Supplementary
Fig. 12a, b). These results strongly suggest that DOX@E-PSiNPs
display strong cellular uptake and intracellular retention with an
excellent cytotoxicity against CSCs.
To evaluate whether DOX@E-PSiNPs possess cross-reactive
cellular uptake and cytotoxicity, murine melanoma B16-F10
CSCs were treated with free DOX, DOX@PSiNPs or DOX@E-
PSiNPs exocytosed from H22 cells. Consistently, DOX@E-
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Fig. 2 Role of autophagy in the exocytosis of PSiNPs. a LC3-I and LC3-II expression in Bel7402 cells treated with 200 μg mL−1 PSiNPs for different time
intervals by western blot. The number underneath each group in the immunoblotting indicates the relative ratio of LC3-II to LC3-I of the corresponding
group. b Confocal ﬂuorescence microscopic images of EGFP-LC3-transfected Bel7402 cells after treatment with 200 μg mL−1 PSiNPs for different time
intervals. Scale bar: 20 μm. c Relative amount of the exocytosed PSiNPs in Bel7402 cells after treatment with 200 μg mL−1 PSiNPs for 6 h, followed by
washing with PBS and then incubating in fresh medium with or without 5 mM of 3-MA, 200 nM of rapamycin or 30 μM of CBZ for another 16 h by ICP-
OES. d Relative amount of the exocytosed PSiNPs in wild type and Atg7−/− MEF cells after treatment with 200 µg mL−1 PSiNPs for 6 h, followed by
washing with PBS and then incubating in fresh medium for 16 h by ICP-OES. Data were represented as mean ± SD (n= 3). *P < 0.05, **P < 0.01 (one-way
ANOVA with Fisher’s LSD test for c and unpaired two-tailed Student’s t test for d). Source data are provided as a Source Data ﬁle
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PSiNPs showed the highest internalization into B16-F10 CSCs
(Fig. 5d) and had the corresponding strongest cytotoxicity against
B16-F10 CSCs compared with free DOX or DOX@PSiNPs
(Fig. 5e, f and Supplementary Fig. 13a, b). Similarly, DOX@E-
PSiNPs exocytosed from B16-F10 cells exhibited the strongest
cellular uptake and cytotoxicity against H22 CSCs (Supplemen-
tary Fig. 14). These results suggest that DOX@E-PSiNPs have a
strong cross-reactive cellular uptake and cytotoxicity against
CSCs, irrespective of their origin. Furthermore, DOX@E-PSiNPs
also demonstrated the highest intracellular internalization and
cross-reactive cytotoxicity against bulk cancer cells, such as H22,
Bel7402 and B16-F10 cells compared with free DOX or
DOX@PSiNPs (Supplementary Fig. 15, 16). Intracellular trafﬁck-
ing analysis of DOX@E-PSiNPs revealed that exosomes and DOX
were internalized into cancer cells together and then colocalized
with lysosomes, followed by DOX translocation to nuclei over
time (Supplementary Fig. 17). Considering that more DOX was
released from DOX@E-PSiNPs under lysosomal acidic pH
(Supplementary Fig. 18), DOX@E-PSiNPs released DOX in
lysosomes to enter nuclei to exert the cytotoxicity. CD54
(ICAM1), a member of the immunoglobulin supergene family,
was found to be involved in the cross-reactive cellular uptake of
DOX@E-PSiNPs by cancer cells, as evidenced by the fact that
DOX@E-PSiNPs exocytosed from B16-F10 and H22 cells
expressed CD54 (Supplementary Fig. 19a), and pretreatment
with CD54 antibody decreased the cellular uptake of DOX@E-
PSiNPs exocytosed from H22 cells by H22 and B16-F10 cells
(Supplementary Fig. 19b). Despite the strong cellular uptake by
tumor cells, DOX@E-PSiNPs exocytosed from H22 cells exhibited
less internalization into human umbilical vein endothelial cells
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(HUVECs). In addition, less DOX@E-PSiNPs exocytosed from
HUVECs cells were internalized into H22 cells compared with
DOX@E-PSiNPs exocytosed from H22 cells (Supplementary
Fig. 20), suggesting the tumor cell targeting capacity of tumor
exosome-coated PSiNPs.
Enhanced tumor accumulation and penetration. Besides efﬁ-
cient cellular uptake and accompanied strong cytotoxicity against
bulk cancer cells and CSCs, an ideal anticancer drug delivery
system following systemic administration should be characterized
by enhanced tumor accumulation and penetration to reach bulk
cancer cells and CSCs. Therefore, the in vivo biodistribution of
DOX@E-PSiNPs was investigated. Mice bearing H22 hepato-
carcinoma tumors were intravenously injected with free DOX,
DOX@PSiNPs or DOX@E-PSiNPs at 0.5 mg kg−1 DOX dosage,
or high dosage of free DOX at 4 mg kg−1. At 24 h after injection,
the tumors and major normal organs (heart, liver, spleen, lung
and kidney) were collected for DOX content measurement.
Although DOX@E-PSiNPs were accumulated in liver at relatively
high level (Fig. 6a), especially Kupffer cells in liver (Supplemen-
tary Fig. 21), less DOX was accumulated in normal organs (heart,
liver, lung and kidney) of DOX@E-PSiNPs-treated mice than that
of high dosage of DOX-treated mice (Fig. 6a). However, DOX@E-
PSiNPs exhibited strong tumor tropism and accumulation, ca. 2.5
and 2.3 times relative to free DOX and DOX@PSiNPs, respec-
tively, comparable to high dosage of free DOX (Fig. 6a). Pre-
treatment with CD54 antibody decreased the tumor accumulation
of DOX@E-PSiNPs, suggesting that similar to the cross-reactive
cellular uptake by cancer cells, CD54 was also involved in the
enhanced tumor accumulation of DOX@E-PSiNPs (Supplemen-
tary Fig. 22). The strong tumor-targeting ability of DOX@E-
PSiNPs was further conﬁrmed in B16-F10 lung metastatic model
(Supplementary Fig. 23).
Furthermore, we addressed the tumor penetration capacity of
DOX@E-PSiNPs. First, tumor spheroids as in vivo-mimetic
tumors were treated with free DOX, DOX@PSiNPs or DOX@E-
PSiNPs for 24 h, and then the tumor spheroids were optically
sectioned using confocal microscopy. The projection images of
DOX ﬂuorescence in tumor spheroids was reconstructed by using
Amira software. DOX ﬂuorescence intensity in both X- and Y-
axis shadows was distinctly stronger in DOX@E-PSiNPs-treated
group than that in free DOX- or DOX@PSiNPs-treated group at
the same depth (Supplementary Fig. 24), suggesting the deep
tumor penetration ability of DOX@E-PSiNPs. Furthermore, the
deep tumor penetration capability of DOX@E-PSiNPs was
investigated in H22 tumor-bearing mice by intravenous injection
of free DOX, DOX@PSiNPs or DOX@E-PSiNPs. Confocal
ﬂuorescence microscopic images clearly showed that DOX@E-
PSiNPs were distributed widely in whole tumor section at 24 h
after injection (Fig. 6b). In contrast, DOX@PSiNPs and free DOX
accumulated more around the blood vessels as indicated by
stronger co-localization with FITC-CD31-labeled endothelial cells
(Fig. 6b). The distance-dependent DOX ﬂuorescence intensity
also conﬁrmed that only ﬂuorescence signal of DOX delivered
with DOX@E-PSiNPs was detectable at ca. 400 µm far away from
the blood vessels, while free DOX or DOX delivered with
DOX@PSiNPs was found at <120 μm away from the blood vessels
(Fig. 6c). Overall, these results show that DOX@E-PSiNPs are
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easy to extravasate from the blood vessels and penetrate into deep
tumor parenchyma. The strong intercellular delivery capacity of
DOX@E-PSiNPs might be responsible for their enhanced tumor
penetration26 (Supplementary Fig. 25), which is regulated by
CD54 expressed on exosomes of DOX@E-PSiNPs (Supplemen-
tary Fig. 26).
Enhanced in vivo enrichment in side population cells. Given
that DOX@E-PSiNPs demonstrate enhanced tumor accumulation
and penetration, as well as efﬁcient cellular uptake by bulk cancer
cells and CSCs, their in vivo enrichment in total tumor cells and
CSCs might be improved. Therefore, we determined the in vivo
DOX accumulation in total tumor cells at 24 h after GFP-
expressing H22 tumor-bearing mice were intravenously injected
with free DOX, DOX@PSiNPs or DOX@E-PSiNPs at DOX
dosage of 0.5 mg kg−1, or high dosage of free DOX at 4 mg kg−1.
The tumor tissues were digested into single cells and the intra-
cellular DOX ﬂuorescence in total GFP-positive tumor cells was
measured by ﬂow cytometry (Fig. 6d). DOX content in the total
GFP-positive tumor cells of mice administrated with DOX@E-
PSiNPs was about 3.2 times of both free DOX- and DOX@P-
SiNPs-treated groups, respectively, even signiﬁcantly higher than
that of free DOX-treated group at high dosage. Subsequently, we
isolated the side population cells from GFP-positive H22 tumors
by ﬂow cytometry and determined the intracellular DOX
ﬂuorescence (Fig. 6e). Similarly, higher DOX ﬂuorescence
intensity was detected in side population cells of DOX@E-
PSiNPs-treated mice compared with that of free DOX-,
DOX@PSiNPs- or high dosage of free DOX-treated group. Col-
lectively, these results reveal that DOX@E-PSiNPs exhibit aug-
mented in vivo enrichment in the total tumor cells and side
population cells after intravenous injection, which further
increases their in vivo anticancer and CSCs killing activity.
Excellent anticancer and CSCs killing activity. The in vivo
anticancer activity of DOX@E-PSiNPs was determined in BALB/c
mice bearing subcutaneous H22 tumors. Free DOX, DOX@P-
SiNPs, DOX@E-PSiNPs exocytosed from H22 cells at DOX
dosage of 0.5 mg kg−1, or free DOX at high dosage of 4 mg kg−1
were intravenously administrated into H22 tumor-bearing mice
once every 3 days for 17 days. The tumors grew very fast, and free
DOX and DOX@PSiNPs at 0.5 mg kg−1 dosage did not sig-
niﬁcantly inhibit the tumor growth compared with PBS and E-
PSiNPs (Fig. 7a, b and Supplementary Fig. 27). In contrast,
DOX@E-PSiNPs at DOX dosage of 0.5 mg kg−1 showed a sig-
niﬁcant anticancer activity, with 91 and 87% reduction in tumor
volume and tumor weight compared to the PBS group, respec-
tively, and even stronger than free DOX at high dosage (Fig. 7a, b
and Supplementary Fig. 27). The excellent anticancer activity
of DOX@E-PSiNPs was further conﬁrmed by increased
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TUNEL-positive apoptotic tumor cells in excised tumor tissues
(Supplementary Fig. 28). Moreover, prolonged survival time was
observed in H22 tumor-bearing mice treated with DOX@E-
PSiNPs (122 days), compared with PBS- (82 days), E-PSiNPs-
(85 days), free DOX- (84 days) or DOX@PSiNPs-treated group
(87 days) at 0.5 mg/kg DOX dosage, or free DOX at 4 mg/kg
dosage (109 days) (Fig. 7c). Importantly, DOX@E-PSiNPs did not
show systemic toxicity to H22 tumor-bearing mice, as evidenced
by body weight (Supplementary Fig. 29), hematoxylin-eosin
(H&E) staining of major organs (Supplementary Fig. 30) and
serological analysis (Supplementary Fig. 31). However, free DOX
at high dosage of 4 mg kg−1 induced cardiotoxicity (Supple-
mentary Fig. 30, 31).
To further assess whether DOX@E-PSiNPs could efﬁciently kill
CSCs, the tumor tissues after treatment were digested into single
cells, and the number of CD133-positive cells (a CSC marker of
liver cancer45) was measured. As a result, CD133-positive cells
were signiﬁcantly inhibited in DOX@E-PSiNPs-treated group,
compared with free DOX-, DOX@PSiNPs-, or high dosage of free
DOX-treated group (Fig. 7d). Consistently, the number of side
population cells in tumor tissues of DOX@E-PSiNPs-treated
GFP-expressing H22 tumor-bearing mice was the fewest
compared with other groups (Fig. 7e). Furthermore, 800 single
tumor cells were seeded in soft 3D ﬁbrin gels (90 Pa) for 5 days,
which was developed to select CSCs42,43. The fewest colony
number and smallest colony size were formed in DOX@E-
PSiNPs-treated group (Fig. 7f, g). The excellent CSCs killing
activity of DOX@E-PSiNPs was further conﬁrmed by subcuta-
neously transplanting the same amounts of tumor cells from
tumor tissues after treatment into BALB/c mice (Fig. 7h). 100% of
mice (6/6 mice) generated tumors at 6 days after secondary
transplantation of tumor cells of PBS-, E-PSiNPs-, free DOX- or
DOX@PSiNPs-treated group. However, 83% (5/6 mice) and 33%
(2/6 mice) of mice generated tumors at 40 days after secondary
transplantation of tumor cells of high dosage of DOX- and
DOX@E-PSiNPs-treated groups, respectively. Taken together,
these results strongly reveal that DOX@E-PSiNPs have excellent
anticancer and CSCs killing activity. To further improve the
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Fig. 7 Anticancer activity of DOX@E-PSiNPs in H22 tumor-bearing mice. a Tumor growth curves of H22 tumor-bearing mice after intravenous injection of PBS,
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arrows indicate the drug injection time. Data were represented as mean ± SD (n= 14). b Weight of tumor tissues at the end of tumor growth inhibition
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anticancer and CSCs killing efﬁcacy, more DOX@E-PSiNPs at
DOX dosage of 0.8 mg kg−1, or the combination of DOX@E-
PSiNPs at DOX dosage of 0.5 mg kg−1 and all-trans-retinoic acid
(ATRA), a powerful differentiating agent of CSCs, were
intravenously injected into H22 tumor-bearing mice. As expected,
increasing the used dosage of DOX@E-PSiNPs, or combination of
DOX@E-PSiNPs and ATRA resulted in a signiﬁcant tumor
inhibition, with 3 or 2 tumor ablation in 6 mice, respectively
(Supplementary Fig. 32a–g). Correspondingly, fewer side popula-
tion cells in tumor tissues (Supplementary Fig. 32h), fewer colony
number (Supplementary Fig. 32i) and smaller colony size
(Supplementary Fig. 32j) after seeding the tumor cells in 3D
ﬁbrin gels were observed in these groups compared with only
DOX@E-PSiNPs treatment group at DOX dosage of 0.5 mg kg−1,
suggesting that CSCs might be responsible for the drug resistance.
Meanwhile, combination treatment of DOX@E-PSiNPs and
ATRA, or increasing the used dosage of DOX@E-PSiNPs was
found to be safe, as evidenced by routine blood test (Supplemen-
tary Fig. 33a–d), serological analysis (Supplementary Fig. 33e–j)
and body weight (Supplementary Fig. 33k).
To further investigate the cross-reactive anticancer and CSCs
killing efﬁcacy of DOX@E-PSiNPs, mice bearing orthotopic
4T1 breast tumors were intravenously administrated with free
DOX, DOX@PSiNPs, DOX@E-PSiNPs exocytosed from H22
cells at DOX dosage of 0.5 mg kg−1 or free DOX at high dosage
of 4 mg kg−1 once every 3 days for 15 days. DOX@E-PSiNPs at
DOX dosage of 0.5 mg kg−1 exhibited a signiﬁcant anticancer
activity, with 68% and 65% reduction in tumor volume and
tumor weight compared to the PBS group, respectively (Fig. 8a,
b). Mice treated with DOX@E-PSiNPs had 11, 10, and 4 days
longer survival time as compared to free DOX and
DOX@PSiNPs at DOX dosage of 0.5 mg kg−1, and free DOX
at 4 mg kg−1 dosage (Fig. 8c). Furthermore, tumor cells
digested from breast tumors after treatment were seeded in
soft 3D ﬁbrin gels (90 Pa). The fewest colony number and
smallest colony size of the formed tumor spheroids were
detected in DOX@E-PSiNPs-treated group (Fig. 8d, e). These
results demonstrate the excellent cross-reactive anticancer and
CSCs killing efﬁcacy of DOX@E-PSiNPs. DOX@E-PSiNPs did
not cause toxicity to 4T1 tumor-bearing mice, as evidenced by
routine blood test (Supplementary Fig. 34), serological analysis
(Supplementary Fig. 35) and H&E staining of major organs
(Supplementary Fig. 36), although free DOX at 4 mg kg−1
dosage caused bone marrow and heart toxicity.
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Fig. 8 Anticancer activity of DOX@E-PSiNPs in orthotopic 4T1 tumor-bearing mice. a Tumor growth curves of orthotopic 4T1 tumor-bearing mice after
intravenous injection of PBS, E-PSiNPs, free DOX, DOX@PSiNPs, DOX@E-PSiNPs exocytosed from H22 cells at DOX dosage of 0.5 mg kg−1, or free DOX
at high dosage of 4mg kg−1. The arrows indicate the drug injection time. Data were represented as mean ± SD (n= 14). b Weight of tumor tissues at the
end of tumor growth inhibition experiments. Data were represented as mean ± SD (n= 6). c Kaplan–Meier survival plot of 4T1 tumor-bearing mice after
intravenous administration of different formulations (n= 8). d, e Relative colony number (d) and size (e) of tumor spheroids when tumor cells digested
from tumor tissues of 4T1 tumor-bearing mice at the end of tumor growth inhibition experiments were seeded in soft 3D ﬁbrin gels for 5 days. Data were
represented as mean ± SD (n= 6). *P < 0.05, ***P < 0.001 (one-way ANOVA with Bonferroni’s multiple comparisons test for a, b, d, e and log-rank test for
c). Source data are provided as a Source Data ﬁle
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Furthermore, the mice model bearing B16-F10 melanoma with
high lung metastasis was developed to evaluate the cross-reactive
anticancer and CSCs killing activity of DOX@E-PSiNPs. At 48 h
after injection of 5 × 105 B16-F10 cells into C57BL/6 mice, the
mice were intravenously administrated with free DOX, DOX@P-
SiNPs, DOX@E-PSiNPs exocytosed from H22 cells at DOX
dosage of 0.5 mg kg−1 or free DOX at high dosage of 4 mg kg−1
once every 3 days for 13 days. Signiﬁcantly fewer metastatic
nodules were detected in the DOX@E-PSiNPs-treated group
(Fig. 9a and Supplementary Fig. 37). The less lung metastasis in
DOX@E-PSiNPs-treated mice was further conﬁrmed by H&E
staining on lungs (Fig. 9b). Mice treated with DOX@E-PSiNPs
had 18, 17, and 4 days longer survival time as compared to free
DOX and DOX@PSiNPs at DOX dosage of 0.5 mg kg−1, and free
DOX at 4 mg kg−1 dosage (Fig. 9c). Furthermore, the fewest
colony number and smallest colony size of the formed tumor
spheroids were detected in DOX@E-PSiNPs-treated group after
seeding the tumor cells digested from lungs in the 3D ﬁbrin gels
(Fig. 9d, e). These results strongly demonstrate the excellent
anticancer and CSCs killing efﬁcacy of DOX@E-PSiNPs, regard-
less of tumor models used and the origin of exosomes used in
DOX@E-PSiNPs. The cross-reactive anticancer treatment of
DOX@E-PSiNPs did not induce immunological reaction, as
evidenced by the fact that treatment with DOX@E-PSiNPs
exocytosed from H22 cells did not affect the content of IgM,
TNF-α, IL-1β, and IL-6 in serum of C57BL/6 mice (Supplemen-
tary Fig. 38).
Discussion
CSCs, a small population of cancer cells with self-renewal and high
tumorigenesis, play an important role in tumor development,
progression and metastasis31,32. Traditional chemotherapeutics kill
bulk tumor cells, but can not efﬁciently eliminate CSCs due to
their overexpression of ATP-binding cassette (ABC) transporters,
antiapoptotic proteins and DNA repair enzymes, resulting in drug
resistance and tumor recurrence after chemotherapy31,32.
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Fig. 9 Anticancer activity of DOX@E-PSiNPs in B16-F10 lung metastasis mice. a Metastatic nodule numbers in lungs of B16-F10 tumor-bearing mice after
intravenous injection of PBS, E-PSiNPs, free DOX, DOX@PSiNPs, DOX@E-PSiNPs exocytosed from H22 cells at DOX dosage of 0.5 mg kg−1, or free DOX
at high dosage of 4 mg kg−1 every three days for 13 days. Data were represented as mean ± SD (n= 6). b H&E staining of lungs of B16-F10 tumor-bearing
mice at the end of tumor growth inhibition experiments. Scale bar: 1000 µm. c Kaplan–Meier survival plot of B16-F10 tumor-bearing mice after intravenous
administration of different formulations (n= 8). d, e Relative colony number (d) and size (e) of tumor spheroids when tumor cells digested from lung
tumor nodules at the end of tumor growth inhibition experiments were seeded in soft 3D ﬁbrin gels for 5 days. Data were represented as mean ± SD (n=
5). **P < 0.01, ***P < 0.001 (one-way ANOVA with Bonferroni’s multiple comparisons test for a, d, e and log-rank test for c). Source data are provided as a
Source Data ﬁle
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Therefore, developing effective therapeutic strategies targeted to
CSCs remains a big challenge for cancer therapy.
Nowadays, some NDDSs have been successfully applied to
target CSCs to treat tumor. These approaches mainly include:
(1) NDDSs were rationally designed to bypass the efﬂux pump
via endocytosis, resulting in higher intracellular accumulation
in CSCs46,47; (2) NDDSs codelivered MDR modulators and
anticancer drugs to CSCs to overcome drug resistance48; and
(3) NDDSs were modiﬁed with CSCs targeting ligands, such as
CD4449, CD13350, and CD9051 to increase speciﬁcity and cel-
lular uptake. Although these NDDSs have shown potentials to
overcome chemoresistance and enhance the accumulation of
anticancer drug in CSCs, they cannot achieve full therapeutic
efﬁcacy. The main reasons lie in: (1) Ideal NDDSs targeting
CSCs should be characterized by enhanced tumor accumula-
tion, tumor penetration and cellular uptake by CSCs to highly
enriched in CSCs following systemic administration52. How-
ever, the above approaches used to target CSCs are difﬁcult to
meet all demands at the same time, hindering the therapeutic
efﬁcacy; (2) There is no universal marker used for CSCs tar-
geting in all cancers since the markers of CSCs differ from one
type of tumor to another, and these markers are often expressed
by other cell types, such as normal stem cells6,7. Thus, targeting
NDDSs to CSCs using these markers is unreliable and risky;
and (3) The constructed nanoparticles usually need compli-
cated synthesis, and are usually toxic and may cause side effects
as foreign components53. In the present study, we developed an
exosome-sheathed PSiNPs to load DOX for efﬁcient CSCs
targeting and killing. DOX@E-PSiNPs not only exhibited
enhanced tumor accumulation and penetration, but also had
strong cross-reactive cellular uptake and cytotoxicity against
CSCs, as evidenced by the fact that DOX@E-PSiNPs exocytosed
from both H22 and B16-F10 cells are efﬁciently internalized
into H22 and B16-F10 CSCs, resulting in the strongest cyto-
toxicity compared with free DOX and DOX@PSiNPs. The
strong cross-reactive cellular uptake of DOX@E-PSiNPs can
overcome the obstacles of requiring the speciﬁc markers for
targeting CSCs in different tumors. Furthermore, DOX@E-
PSiNPs signiﬁcantly decreased P-gp expression in CSCs,
enhancing DOX retention in CSCs to overcome drug resistance.
Therefore, DOX@E-PSiNPs efﬁciently integrated all features to
eradicate CSCs, generating remarkable anticancer and CSCs
killing activity in H22 tumor-bearing BALB/c mice, othotopic
4T1 tumor-bearing mice and B16-F10 tumor-bearing C57BL/6
mice. No signiﬁcant toxicity of DOX@E-PSiNPs was observed
in tumor-bearing mice by serological and histopathological
analysis. Moreover, DOX@E-PSiNPs exocytosed from H22
cells, which were originated from liver cancer ascites of BALB/c
mice, did not induce immune response in C57BL/6 mice, sug-
gesting that DOX@E-PSiNPs are biocompatible and safe.
Upon autophagy induction, cytoplasmic materials are seques-
tered in double-membrane vesicles termed autophagosomes,
which can fuse with MVBs to form amphisomes or directly
deliver to the lysosomes for degradation35. Thus, the induction of
autophagy usually inhibits the release of exosomes54. However,
when the cells can not degrade material in the lysosomes due to
the lysosomal defect, lysosomal overload or transport inter-
ference, the contents of lysosomes, MVBs or amphisomes are
exocytosed as exosomes when fusing with cell membrane53.
Several nanoparticles, such as silver nanoparticles55, carbon-
based nanoparticles56 or silicon-based nanoparticles57, were
reported to induce autophagy. In this work, E-PSiNPs used as an
anticancer drug carrier, were exocytosed from cancer cells in an
autophagy-dependent manner. The possible reason is due to the
unique structure of PSiNPs, which cannot be degraded under
lysosomal acidic microenvironment58 (Supplementary Fig. 39),
promoting cancer cells to release exosome-coated PSiNPs. The
exocytosed E-PSiNPs might keep the protein integrity on exo-
some membranes, which can display fully the biological function
of exosomes during drug delivery.
In summary, we have successfully developed biocompatible
exosome-sheathed PSiNPs for targeted cancer chemotherapy.
DOX@E-PSiNPs are exocytosed from tumor cells after incubation
with DOX@PSiNPs. Following intravenous injection, DOX@E-
PSiNPs exhibit enhanced tumor accumulation, tumor penetration
and cross-reactive cellular uptake by bulk cancer cells and CSCs,
resulting in augmented in vivo DOX enrichment in total tumor
cells and side population cells. DOX@E-PSiNPs further demon-
strate signiﬁcant cross-reactive anticancer and CSCs killing
activity in both subcutaneous transplantation tumor models,
orthotopic tumor models and the advanced metastatic tumor
models. Our study clearly demonstrates that exosome-biomimetic
nanoparticles have potential as drug carriers to improve the
anticancer efﬁcacy.
Methods
Materials. Boron-doped p-type silicon wafers (0.8–1.2 mΩ cm resistivity, 〈100〉
orientation) were produced from Virginia Semiconductor, Inc. (Fredericksburg,
VA, USA). Doxorubicin hydrochloride (DOX·HCl, with purity > 98.0%) was
obtained from Beijing HuaFeng United Technology CO., Ltd. (Beijing, China).
RPMI 1640 medium, Dulbecco’s Modiﬁed Eagle’s Medium (DMEM), FBS, peni-
cillin and streptomycin were provided by Gibco BRL/Life Technologies (Grand
Island, NY, USA). Fibrinogen and thrombin were purchased from Searun Holdings
Company (Freeport, ME, USA). Collagenase type I was purchased from Thermo
Fisher Scientiﬁc (Waltham, MA, USA). Dispase II and TUNEL assay kit were
purchased from F. Hoffmann-La Roche Ltd (Basel, Switzerland). Anti ICAM-1
antibody and anti P-gp antibody were purchased from ProteinTech (Wuhan,
China). DIO, ionomycin, Hoechst 33342 and BCA protein quantiﬁcation kit were
purchased from Beyotime Biotechnology (Shanghai, China). Verapamil was pro-
vided by Selleck Chemicals (Houston, TX, USA). Cell counting kit (CCK-8) assay
was obtained from Biosharp Company (Shanghai, China). DMA was purchased
from Sigma-Aldrich (St Louis, MO, USA). All other reagents were of analytical
grade and used without any further puriﬁcation.
Cell lines and animals. Murine hepatocarcinoma cell line H22, mouse breast
cancer cell line 4T1 and human hepatocarcinoma cell line Bel7402 were obtained
from Type Culture Collection of Chinese Academy of Sciences (Shanghai, China).
Murine melanoma cell line B16-F10 was kindly provided by Dr. Bo Huang
(Huazhong University of Science and Technology, Wuhan, China). Wild type
MEFs and Atg7−/− MEFs were kindly provided by Dr. Mingzhou Chen (Wuhan
University, Wuhan, China). H22 cells were cultured in RPMI 1640 medium, and
Bel7402 cells, wild type and Atg7−/− MEFs and B16-F10 cells were cultured in
DMEM medium at 37 °C in a 5% CO2 humidiﬁed incubator. All media contained
10% FBS, 100 U mL−1 penicillin and 100 μg mL−1 streptomycin. Six- to eight-
week-old BALB/c mice (male and female) and C57BL/6 mice (male) were pur-
chased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing,
China). H22 tumor-bearing mice were constructed by subcutaneously injecting
106 H22 cells per mouse into the ﬂanks of male BALB/c mice. Orthotopic 4T1
breast tumor mode was constructed by injecting 2 × 105 4T1 cells to the right
mammary fat pad of female BALB/c mice. B16-F10 lung metastasis tumor model
was constructed by intravenously injecting 5 × 105 B16-F10 cells per mouse into
C57BL/6 mice. All animal experiments comply with relevant ethical regulations for
animal testing and research, and were approved by the Institutional Animal Care
and Use Committee at Tongji Medical College, Huazhong University of Science
and Technology (Wuhan, China). All cell lines were routinely tested for myco-
plasma infection and were found to be negative by MycAway-Color one-step
mycoplasma detection kit.
CSC culture. CSCs were selected by soft 3D ﬁbrin gels42,43. Fibrinogen was diluted
to 2 mgmL−1 with T7 buffer (50 mM Tris, pH 7.4, 150 mM NaCl) and then
ﬁbrinogen/cell mixtures were obtained by blending 2 mgmL−1 ﬁbrinogen with
similar volume of cell solution (2 × 103 cells per mL), which produced gels of 90 Pa
in elastic stiffness. 250 μL mixtures were loaded into each well of 24-well plate pre-
added with 5 μL thrombin (0.1 U μL−1). The cell culture plate was then incubated
at 37 °C for 30 min. Finally, 1 mL RPMI 1640 medium containing 10% FBS and
antibiotics were added. On the ﬁfth day, tumor spheroids were obtained and
digested into single cells using 0.08% collagenase type I and 0.4% dispase II for
20 min at 37 °C.
Preparation of PSiNPs and DOX@PSiNPs. PSiNPs were prepared by electro-
chemical etching method25–28. Brieﬂy, boron-doped p-type silicon wafers were
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immersed into an aqueous solution of hydroﬂuoric acid (HF) and ethanol (4:1, v/v)
in a Teﬂon etch cell, and then subjected to etch at a constant current density of
165 mA cm−2 for 300 s. The rufous porous silicon ﬁlm on the substrate was
removed in 3.3% aqueous HF solution in ethanol at a constant current of
4.5 mA cm−2 for 90 s, fragmented in ultrapure water by ultrasonication overnight,
and then centrifuged at 10,000 g for 20 min to collect PSiNPs. Finally, PSiNPs were
heated at 60 °C for 3 h to activate photoluminescence.
DOX@PSiNPs were prepared by adding PSiNPs in DOX solution at a weight
ratio of 10:3 and then stirring for 12 h at room temperature. The mixtures were
centrifuged at 10,000 g for 10 min to collect DOX@PSiNPs, followed by gently
washing with ultrapure water twice to eliminate free DOX.
Autophagy induced by PSiNPs. H22 or Bel7402 cells were treated with 200 μg mL
−1 PSiNPs for 6 h. After washing with PBS for three times, cells were lysed in RIPA
lysis buffer and then subjected to western blot analysis. Brieﬂy, 200 μg of lysates
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE, 15% gel) and transferred onto nitrocellulose membranes. The membranes
were blocked by 5% BSA for 2 h, and then incubated with anti-LC3 (Novus,
NB100-2331SS) and anti-β-actin antibody (Beyotime, AA128, diluted to 1:2,000) at
4 °C overnight. After washing with Tris-buffered saline containing 0.1% Tween-20
(TBST), the membranes were incubated with horseradish peroxidase (HRP)-
labeled secondary antibody (Beyotime, A0216, A0208, diluted to 1:10,000) at 37 °C
for 2 h. The protein bands were detected using enhanced chemiluminescence (ECL)
reagent and analyzed on ChemiDoc XRS Gel image system (Bio-Rad, Hercules,
CA, USA). Uncropped gel images are provided in Source Data ﬁle.
Bel7402 cells were transfected with EGFP-LC3 plasmid by electroporation.
After 24 h transfection, the cells were treated with 200 μg mL−1 PSiNPs for 6 h,
washed with PBS for three times and then ﬁxed with 4% paraformaldehyde. Green
ﬂuorescence of LC3 proteins were visualized by FV1000 confocal microscope
(Olympus, Japan).
Preparation and characterization of DOX@E-PSiNPs. To prepare E-PSiNPs or
DOX@E-PSiNPs, 5 × 107 H22, Bel7402, or B16-F10 cells were treated with PSiNPs
(at silicon concentration of 200 μg mL−1) or DOX@PSiNPs (at DOX concentration
of 10 μg mL−1) for 6 h in 10 cm dishes. Subsequently, the media were discarded
and replaced with fresh one without PSiNPs or DOX@PSiNPs. After 16 h incu-
bation, the debris was discarded at 5,000 g for 15 min and then the supernatants
were further centrifuged at 20,000 g for 30 min to pellet out E-PSiNPs or DOX@E-
PSiNPs. Then, the obtained pellets were washed with PBS and resuspended in PBS
for further experiments. DOX loading into E-PSiNPs was conﬁrmed by labeling
DOX@E-PSiNPs with DiO and then observed by FV1000 confocal microscopy.
The DiO ﬂuorescence was detected at the excitation wavelength of 488 nm and the
emission range of 500–520 nm, DOX at the excitation wavelength of 559 nm and
the emission range of 570–600 nm, and PSiNPs at the excitation wavelength of 488
and the emission range of 670–690 nm. The hydrodynamic diameter of E-PSiNPs
and DOX@E-PSiNPs was determined by DLS (ZetaSizer ZS90, Malvern Instru-
ments Ltd., Worcestershire, UK). The morphology of E-PSiNPs was observed by
TEM (Tecnai G2-20, FEI Corp., Netherlands). DOX content loaded into DOX@E-
PSiNPs was determined by incubating in 1M NaOH for 30 min to dissolve E-
PSiNPs, neutralizing with equal volume of 1M HCl and then detecting DOX
content by HPLC.
Exosome puriﬁcation. Exosomes were puriﬁed using differential ultracentrifuga-
tion method37,38. First, FBS used for cell incubation was centrifuged at 100,000 g
overnight to wipe out the existing exosomes. H22 or Bel7402 cells were incubated
in exosome-free RPMI 1640 or DMEM medium for 48 h. Cell culture medium was
collected and sequentially centrifuged at 1000 g for 10 min, 10,000 g for 30 min and
100,000 g for 1 h to pellet exosomes. Exosomes were washed with PBS and
recovered by centrifugation at 100,000 g for 1 h.
Conﬁrmation of exosomes sheathed on PSiNPs in E-PSiNPs. E-PSiNPs were
stained with 10 μM DiO for 30 min, centrifuged at 20,000 g for 30 min and then
washed with PBS three times. The colocalization of DiO and PSiNPs was observed
by FV1000 confocal microscopy. The ﬂuorescence of DiO at 500–520 nm and
PSiNPs at 670–690 nm was detected at the excitation of 488 nm.
E-PSiNPs was blocked by 5% BSA for 30 min, and then incubated with FITC-
conjugated CD63 antibody (Biolegend, 353005, diluted to 1:200) for 30 min at
room temperature. The colocalization of CD63 and PSiNPs was observed by
FV1000confocal microscopy. The ﬂuorescence of FITC at 500–520 nm and PSiNPs
at 670–690 nm was detected at the excitation of 488 nm.
Whole cells, the puriﬁed exosomes and E-PSiNPs were lysed in RIPA lysis
buffer and then subjected to western blot analysis. The primary antibodies used
included anti-CD63 (Abcam, ab216130), anti-TSG101 (Santa Cruz, SC-7964) and
anti-calnexin (Beyotime, AC018). All primary antibodies were diluted to 1:2000.
Uncropped gel images are provided in Source Data ﬁle.
E-PSiNPs yield. Bel7402 cells were incubated with 200 μg mL−1 PSiNPs for 6 h
and washed with PBS three times. Then fresh medium containing 200 nM
rapamycin, 30 μM CBZ, 5 mM 3-MA, 15 nM DMA or 10 μM ionomycin were
added. After 16 h incubation, the supernatants were collected, centrifuged at 5000 g
for 15 min to remove debris, and then centrifuged at 20,000 g for 30 min. The
pellets were dissolved in 1 M NaOH solution and silicon content was measured by
Optima 4300 DV ICP-OES (PerkinElmer, Norwalk, CT, USA).
In vitro DOX release proﬁle. DOX release proﬁle from DOX@E-PSiNPs was
determined by dialysis method. Brieﬂy, DOX@E-PSiNPs (300 μg DOX content)
were put into a dialysis bag (cutoff molecular weight was 3000 Da) and submerged
fully into PBS (30 mL), then stirred with 250 rpm at 37 °C. At the designated time
intervals, 0.5 mL of sample solution was taken out and replaced with equal amount
of fresh PBS. DOX content in samples was measured by HPLC.
Interaction between DOX@E-PSiNPs and CSCs by AFM. H22 CSCs were seeded
on coverslips pretreated with poly-lysine in 6-well plates at a density of 3 × 105 cells
per well. H22 CSCs were then incubated with DOX, DOX@PSiNPs or DOX@E-
PSiNPs at the DOX concentration of 2 µg mL−1 at 37 °C for 2 h. After washing
with PBS, CSCs were ﬁxed with 0.25% (v/v) glutaraldehyde for 30 min at room
temperature. The coverslips were rinsed with deionized water to remove salt
crystals and air dried before analysis. AFM images were obtained using a multi-
mode 8 AFM (Bruker, Santa Barbara, CA, USA). Cell surface studies were per-
formed in ScanAsys mode at scan frequencies below 1 Hz. The roughness of CSCs
membrane was analyzed by measurement of Image Rq.
Cell membrane ﬂuidity. H22 CSCs membrane ﬂuidity was measured using
ﬂuorescence polarization of 1,6-diphenyl-1,3,5-hexatriene (DPH)59. Brieﬂy, H22
CSCs (106 cell per mL) were incubated with DPH (2 μM) at 37 °C for 1 h. The
labeled CSCs were then incubated with DOX, DOX@PSiNPs or DOX@E-PSiNPs at
the DOX concentration of 2 μg mL−1 for 2 h. Fluorescence anisotropy was mea-
sured using a polarization spectroﬂuorometer (FP-6500, Jasco, Tokyo, Japan) with
an excitation wavelength of 365 nm and an emission wavelength of 429 nm. Ani-
sotropy was calculated as: r= (IVV− IVH.G)/(IVV+ IVH.G), where G= IHV/IHH is
used to correct the unequal transmission of the optics.
Internalization into bulk cancer cells and CSCs. Bel7402 and H22 cells, and H22
and B16-F10 CSCs selected in soft 3D ﬁbrin gels were seeded into six-well plates
overnight at a density of 2 × 105 cells per well. Subsequently, cells were incubated
with free DOX, DOX@PSiNPs or DOX@E-PSiNPs at different DOX concentra-
tions for 2 h, rinsed with PBS and then collected to analyze the intracellular DOX
ﬂuorescence in FL2 channel by ﬂow cytometry (FC500, Beckman Coulter, Full-
erton, CA, USA).
Cytotoxicity against bulk cancer cells and CSCs. For determination of DOX@E-
PSiNPs against bulk cancer cells, Bel7402, H22 and B16-F10 cells were seeded in
96-well plate at a density of 8 × 103 cells per well overnight and then treated with
free DOX, DOX@PSiNPs or DOX@E-PSiNPs at different DOX concentrations.
After 24 h treatment, cell survival rate was detected by CCK-8 assay.
To evaluate cytotoxicity of DOX@E-PSiNPs against CSCs, H22 and B16-F10
cells were pre-treated with DOX, DOX@PSiNPs or DOX@E-PSiNPs at different
DOX concentrations for 4 h. The cells were harvested, washed and counted. 4 × 102
cells from different groups were then seeded in 3D ﬁbrin gels. On the ﬁfth day, the
numbers of tumor spheroids in different groups were counted under Olympus IX
71 optical microscope (Tokyo, Japan). Tumor spheroids in each group were imaged
and their sizes were calculated by Image J software.
To further determine cytotoxicity of DOX@E-PSiNPs against CSCs, H22 and
B16-F10 CSCs were selected in 3D ﬁbrin gels in 96-well plates. On day 5, the media
were aspirated and fresh media containing DOX, DOX@PSiNPs or DOX@E-
PSiNPs at DOX concentration of 2 μg mL−1 were added. After 24 h incubation,
tumor spheroids with integral rims in each group were counted under optical
microscope. The images of tumor spheroids in each group were captured and their
sizes were calculated by Image J software.
In vivo biodistribution. When tumor volume of H22 tumor-bearing mice reached
ca. 250 mm3, or at 13 days after intravenous injection of B16-F10 cells into C57BL/
6 mice, the mice were intravenously injected with free DOX, DOX@PSiNPs or
DOX@E-PSiNPs exocytosed from H22 cells at DOX dosage of 0.5 mg kg−1, or free
DOX at high dosage of 4 mg kg−1. At 24 h post-injection, the mice were sacriﬁced,
and the major organs (heart, liver, spleen, lung and kidney) and tumors in H22
tumor-bearing mice and lung metastatic nodules in B16-F10 tumor-bearing mice
were collected. Subsequently, tissues were lysed and DOX was extracted by incu-
bating the lysates in 1M NaOH for 30 min and neutralizing by the same volume of
1 M HCl. DOX contents in the lysates were tested by a FlexStation3 Multi-Mode
Microplate Reader (Molecular Devices, Sunnyvale, CA, USA).
In vitro penetration in 3D tumor spheroids. H22 tumor spheroids were con-
structed using soft 3D ﬁbrin gel method as described above. To observe penetration
of DOX@E-PSiNPs from outside of tumor spheroids to core area, tumor spheroids
with diameter of ca. 150–200 μm were treated with free DOX, DOX@PSiNPs or
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DOX@E-PSiNPs exocytosed from H22 cells at DOX concentration of 2 μg mL−1
for 24 h. The spheroids were washed with PBS twice, ﬁxed with 4% paraf-
ormaldehyde for 30 min, and then transferred to confocal dishes. DOX red
ﬂuorescence at 570−590 nm was observed by confocal microscopy using Z-stack
scanning mode at the intervals of 5 μm at the excitation of 559 nm. The 3D DOX
ﬂuorescence images in tumor spheroids were reconstructed by using Amira
software.
In vivo tumor penetration. When tumor volume of H22 tumor-bearing mice
reached ca. 250 mm3, the mice were intravenously injected with DOX, DOX@P-
SiNPs or DOX@E-PSiNPs exocytosed from H22 cells at DOX dosage of 0.5 mg kg
−1. At 24 h post-injection, tumor tissues were collected, washed with PBS, and then
frozen-sectioned into pieces. The sections were incubated with FITC-CD31 anti-
body (Biolegend, 102405, diluted to 1:200) at 37 °C for 30 min to label tumor
vessels, and then rinsed with PBS. DOX red ﬂuorescence at 570−600 nm and
FITC-CD31 green ﬂuorescence at 500−520 nm were observed by confocal
microscopy at the excitation of 559 nm or 488 nm, respectively. DOX distribution
from blood vessels to deep tumor tissues was measured by Image J Software.
Intercellular delivery. H22 cells were seeded on coverslips, which were pretreated
with 10 µg mL−1 poly-lysine overnight. Cells on the ﬁrst coverslip were treated
with 2 μg mL−1 DOX, DOX@PSiNPs or DOX@E-PSiNPs for 6 h. The treated cells
were rinsed with PBS and then co-incubated with the new cells on the second
coverslip for 16 h in fresh medium. Finally, the cells on the second coverslip were
co-incubated with the new cells on the third coverslip for another 16 h in fresh
medium. Cells were rinsed with PBS and the intercellular DOX ﬂuorescence at
570–600 nm were analyzed by confocal microscope at the excitation of 559 nm and
ﬂow cytometry (FL2 channel).
In vivo DOX accumulation in total tumor cells and CSCs. When tumor volume
of GFP-expressing H22 tumor-bearing mice reached ca. 250 mm3, the mice were
intravenously injected with free DOX, DOX@PSiNPs or DOX@E-PSiNPs exocy-
tosed from H22 cells at DOX dosage of 0.5 mg kg−1, or free DOX at high dosage of
4 mg kg−1. At 24 h after injection, tumor tissues were collected, washed with PBS
and then cut into small pieces, followed by digestion with 1 mgmL−1 collagenase
type I solution at 37 °C for 2 h. The single tumor cells were acquired by ﬁltering the
digested cells with 200-mesh nylon twice and then divided into two parts. One part
was used to determine DOX content in total GFP-positive tumor cells by ﬂow
cytometry in FL2 channel. The other one was applied to determine DOX content in
side population cells of GFP-positive tumor cells. The tumor cells were treated with
5 μg mL−1 Hoechst 33342 for 90 min in the presence or absence of 50 μm ver-
apamil at 37 °C in the dark. Living cells were plotted on SSC-A and FSC-A graph.
Hoechst 33342 ﬂuorescence at 450 nm or 660 nm in living GFP-positive tumor
cells was measured. The gating of side population cells was plotted as the absence
of cell population in PBS-treated group comparted with verapamil-treated group.
DOX ﬂuorescence intensity in side population cells was detected by ﬂow cytometry
(FL2 channel).
Anticancer activity in subcutaneous H22 tumor-bearing mice. When tumor
volume of H22 tumor-bearing mice reached ca. 200 mm3, the mice were intrave-
nously injected with PBS, E-PSiNPs, free DOX, DOX@PSiNPs, DOX@E-PSiNPs
exocytosed from H22 cells at DOX dosage of 0.5 mg kg−1, or free DOX at high
dosage of 4 mg kg−1 once every three days (n= 14 per group). The tumor sizes
were measured every day via vernier caliper and the body weights of mice were also
recorded. On 17th day of treatment, mice were further divided into two groups.
One group (n= 8) was used for survival experiment, while the other part (n= 6)
was used to estimate anticancer efﬁcacy. For anticancer efﬁcacy analysis, mice were
sacriﬁced, and tumors and major organs (heart, liver, spleen, lung and kidney) were
obtained and washed with PBS. The cleaned tumors were weighed and ﬁxed with
4% paraformaldehyde, then sectioned and stained using a TUNEL assay kit
according to the manufacturer’s protocol. The major organs were also ﬁxed with
4% paraformaldehyde, sectioned and examined by H&E staining.
To estimate CSCs killing activity of DOX@E-PSiNPs in vivo, tumor tissues were
digested into single cells after treatment as above using 1 mgmL−1 collagenase type
I solution. One part of cells were used to determine the number of CD133-positive
cells by ﬂow cytometry. The second part of cells were seeded in soft 3D ﬁbrin gels
(400 cells per well) and incubated for 5 days42,43. The numbers of tumor spheroids
were counted under optical microscope. The images of tumor spheroids were
captured and their sizes were calculated by Image J software. The third part of cells
were subcutaneously transplanted into BALB/c mice (106 cells per mouse) and the
tumor formation ratio was evaluated. Furthermore, the anticancer treatment was
performed in the GFP-expressing H22-tumor bearing mice as above. On 17th day
of treatment, the mice were sacriﬁced and tumor tissues were digested into single
cells. The cells were dyed with 5 μg mL−1 Hoechst 33342 for 90 min at 37 °C in the
presence or absence of 50 μM verapamil in the dark, then washed and resuspended
in PBS. The number of side population cells in GFP-positive tumor cells was
measured by ﬂow cytometry (450/45 BP ﬁlter for blue ﬂuorescence and 660/20 BP
ﬁlter for red ﬂuorescence).
Anticancer activity in orthotopic 4T1 breast cancer mode. 4T1 cells (2 × 105
cells) were suspended in 50 μL PBS and then injected into the right forth breast fat
pad. When the tumor volume reached 50–70 mm3, the mice were administrated
with PBS, E-PSiNPs, free DOX, DOX@PSiNPs or DOX@E-PSiNPs at DOX dosage
of 0.5 mg kg−1, or high dosage of DOX at 4 mg kg−1 once every three days for ﬁve
times (n= 14 per group). The tumor sizes were measured every day via vernier
caliper. On 15th day of treatment, mice were further divided into two groups. One
group (n= 8) was used for survival experiment, while the other part (n= 6) was
used to estimate anticancer efﬁcacy.
To investigate CSCs killing activity of DOX@E-PSiNPs in vivo, tumor tissues
were collected and digested into single cells using 1 mgmL−1 collagenase type I
solution. The cells (400 tumor cells per well) were seeded in soft 3D ﬁbrin gels. On
day 5, the numbers of tumor spheroids were counted under optical microscope.
The images of tumor spheroids were captured and their sizes were calculated by
Image J software.
Anticancer activity in B16-F10 lung metastasis cancer model. At 48 h after B16-
F10 cells (5 × 105 cells per mouse) were intravenously injected into C57BL/6 mice,
the mice were intravenously administrated with PBS, E-PSiNPs, free DOX,
DOX@PSiNPs, DOX@E-PSiNPs exocytosed from H22 cells at DOX dosage of
0.5 mg kg−1, or free DOX at high dosage of 4 mg kg−1 once every three days (n=
14 per group). On 13th day of treatment, mice were divided into two parts. One
part (n= 8) was used for long-term survival experiment and the other part (n= 6)
was used for evaluation of anticancer effect. For evaluation of anticancer effect, the
mice were sacriﬁced and the lungs were acquired. The numbers of tumor nodules
on the surface of lungs were recorded. Lungs were then ﬁxed with 4% paraf-
ormaldehyde, sectioned and examined by H&E staining.
To investigate CSCs killing activity of DOX@E-PSiNPs in vivo, tumor nodules
were collected and digested into single cells using 1 mgmL−1 collagenase type I
solution. The cells (400 tumor cells per well) were seeded in soft 3D ﬁbrin gels. On
day 5, the numbers of tumor spheroids were counted under optical microscope.
The images of tumor spheroids were captured and their sizes were calculated by
Image J software.
Immune response. C57BL/6 mice were intravenously injected with PBS, E-
PSiNPs, DOX, DOX@PSiNPs, DOX@E-PSiNPs exocytosed from H22 cells at the
DOX dosage of 0.5 mg kg−1, or free DOX at high dosage of 4 mg kg−1. At different
time intervals, the orbital blood was obtained, maintained for 30 min and cen-
trifuged at 10,000 g for 10 min. The serum was collected and the contents of IgM,
IL-1β, IL-6, and TNF-α were analyzed by enzyme linked immunosorbent assay
(ELISA).
Statistical analysis. Experiments were performed with at least three replicates. All
values were presented as mean values ± SD. Statistical analyses were carried out
using the GraphPad Prism software version 6.0. Comparison between two groups
was performed using unpaired two-tailed Student’s t test. One-way ANOVA or
two-way ANOVA was used for comparison of more than two groups. Statistical
signiﬁcance for survival curves was determined using a log-rank test. Values with P
< 0.05 are considered signiﬁcant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the main data supporting the ﬁndings of this study are
available within the article and its Supplementary Information. Extra data are available
from the corresponding author upon reasonable request. The source data underlying
Figs. 2–9 and Supplementary Figs. 1–39 are provided with the paper as a Source Data
ﬁle. A reporting summary for this article is available as a Supplementary
Information ﬁle.
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dation (28001830K1 and 4704580), HiLIFE Research Funds and the European Research
Council proof-of-concept grant (decision no. 825020). We thank the Research Core
Facilities for Life Science (HUST), the Analytical and Testing Center of Huazhong
University of Science and Technology and Wuhan institute of biotechnology for related
analysis.
Author contributions
L.G., H.A.S., and X.Y. designed the project. T.Y., Xiaoqiong Z., N.B., H.Z., Xuting Z., F.L.,
A.H., and J.H. performed the experiments. T.Y., Xiaoqiong Z., N.B., H.Z., L.G., H.A.S.
and X.Y. analyzed and interpreted the data, and wrote the paper
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11718-4 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:3838 | https://doi.org/10.1038/s41467-019-11718-4 | www.nature.com/naturecommunications 15
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-11718-4.
Competing interests: The authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Peer review information: Nature Communications thanks Jeffery Coffer and other
anonymous reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-11718-4
16 NATURE COMMUNICATIONS |         (2019) 10:3838 | https://doi.org/10.1038/s41467-019-11718-4 | www.nature.com/naturecommunications
